Evidence map›Paper›PMID 32751747›Full record

ReviewInternational journal of molecular sciences2020

Induced Pluripotent Stem Cells: Hope in the Treatment of Diseases, including Muscular Dystrophies.

Daniela Gois Beghini, Samuel Iwao Horita, Cynthia Machado Cascabulho, Luiz Anastácio Alves, Andrea Henriques-Pons

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Advanced therapy to cure diabetes: mission impossible is now possible?Frontiers in cell and developmental biology · 2024
    Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Reprogramming: Emerging Strategies to Rejuvenate Aging Cells and Tissues.International journal of molecular sciences · 2021
    Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Daniela Gois BeghiniLaboratório de Inovações em Terapias, Ensino e Bioprodutos, 2- Laboratório de Comunicação Celular, both at the Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro RJ 21040-900, Brazil.
Samuel Iwao HoritaLaboratório de Inovações em Terapias, Ensino e Bioprodutos, 2- Laboratório de Comunicação Celular, both at the Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro RJ 21040-900, Brazil.
Cynthia Machado CascabulhoLaboratório de Inovações em Terapias, Ensino e Bioprodutos, 2- Laboratório de Comunicação Celular, both at the Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro RJ 21040-900, Brazil.
Luiz Anastácio AlvesLaboratório de Inovações em Terapias, Ensino e Bioprodutos, 2- Laboratório de Comunicação Celular, both at the Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro RJ 21040-900, Brazil.
Andrea Henriques-PonsLaboratório de Inovações em Terapias, Ensino e Bioprodutos, 2- Laboratório de Comunicação Celular, both at the Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro RJ 21040-900, Brazil.ORCID 0000-0001-9136-240X
Fundação Oswaldo Cruz · BR

Funding

SUBTHRESHOLD MUSCLE AFFERENT INPUT TO DORSAL HORNF06TW002012 · FIC · UNIVERSITY OF CALIFORNIA DAVIS · PI KAUFMAN, MARC PETER · 1995 to 1995
–
Conselho Nacional de Desenvolvimento Científico e Tecnológico 407711/2012-0 and 421803/2017-7Instituto Oswaldo Cruz NA
6 · The paper itself

Abstract

Induced pluripotent stem (iPS) cells are laboratory-produced cells that combine the biological advantages of somatic adult and stem cells for cell-based therapy. The reprogramming of cells, such as fibroblasts, to an embryonic stem cell-like state is done by the ectopic expression of transcription factors responsible for generating embryonic stem cell properties. These primary factors are octamer-binding transcription factor 4 (Oct3/4), sex-determining region Y-box 2 (Sox2), Krüppel-like factor 4 (Klf4), and the proto-oncogene protein homolog of avian myelocytomatosis (c-Myc). The somatic cells can be easily obtained from the patient who will be subjected to cellular therapy and be reprogrammed to acquire the necessary high plasticity of embryonic stem cells. These cells have no ethical limitations involved, as in the case of embryonic stem cells, and display minimal immunological rejection risks after transplant. Currently, several clinical trials are in progress, most of them in phase I or II. Still, some inherent risks, such as chromosomal instability, insertional tumors, and teratoma formation, must be overcome to reach full clinical translation. However, with the clinical trials and extensive basic research studying the biology of these cells, a promising future for human cell-based therapies using iPS cells seems to be increasingly clear and close.

Indexed as

Cellular ReprogrammingGene Expression Regulation, DevelopmentalHumansInduced Pluripotent Stem CellsKruppel-Like Factor 4Kruppel-Like Transcription FactorsMuscular DystrophiesOrganic Cation Transporter 3Organic Cation Transport ProteinsProto-Oncogene MasProto-Oncogene Proteins c-mycSOXB1 Transcription FactorsKLF4 protein, humanKruppel-Like Factor 4Kruppel-Like Transcription FactorsMAS1 protein, humanMYC protein, humanOrganic Cation Transporter 3Organic Cation Transport ProteinsProto-Oncogene MasProto-Oncogene Proteins c-mycSOX2 protein, humanSOXB1 Transcription Factorscellular therapyinduced pluripotent stem cellsmuscular dystrophyregenerationstem cells

Identifiers

PMID32751747
PMCPMC7432218
OpenAlexW3045863552

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.